Research Programmes
Do you know…
- … the scientists in CEITEC will be researching what happens in the brain when a human has realized that they have made a mistake?
- … there will be nearly 800 scientists in CEITEC?
- … in CEITEC we will be researching how the brain works and why some people are motivated and others are not?
- … thanks to CEITEC most of the diagnostic methods will be cheaper, faster and more comfortable for the patients?
- … 63 research teams will be created in CEITEC?
- … there will be 7 research programmes in CEITEC?
- … there will be more than 1,000 modern instruments in CEITEC?
- … more than 31,000 m2 of new infrastructure will be built in CEITEC?
- … more than 1,500 students will use the CEITEC infrastructure per year?
- … there will be 10 shared laboratories created in CEITEC?
- … CEITEC has 6 partners?
- … work will be carried out on self-cleaning surfaces in CEITEC?
- … CEITEC will co-operate closely with the industrial sector?
- … there will also be international scientists working in CEITEC?
- … CEITEC will support the international mobility of scientists?
- … the scientists in CEITEC are developing a subdermal chip which will analyse some life functions and will inform doctors from a distance?
- … the scientists in CEITEC are working on the development of a device which will enable physiotherapy from a distance?
- … the scientists at CEITEC are working on the development of biosensors?
- … CEITEC will be created in the south-Moravian city of Brno?
Core Facility – Genomics
MVDr. Boris Tichý, Ph.D.
Research Group Leader
THEMATIC RESEARCH FOCUS
RESEARCH AREAS
- Operation of the Genomics Core Facility
- New technologies in medical diagnostics
- Improvement and new applications of molecular biology technologies
MAIN OBJECTIVES
Introduction of high-throughput analyses (whole genome sequencing and transcriptome profiling) of human and microbial genomes. Utilisation of these technologies in medicine and development of diagnostic tests based on the high-throughput methods. Mutational analyses of human cells in relation to cancer, neuromuscular, neurodegenerative, metabolic and skin disorders; the detection of novel prognostic markers.
CONTENT OF RESEARCH
Genomics Core Facility
The recent development of novel high-throughput approaches for analyses of human genome influences many fields in biomedical research and clinical medicine. Microarray approaches performed both for genome-wide analyses and gene expression analyses have been widely used in the last decade and enabled a discovery of many biomarkers, which have already found their way into routine medical diagnostics. The introduction of the “next-generation” or massively parallel DNA sequencing, which allows sequencing of whole human genomes in just a few days, has brought novel potential into medicine and will definitely give an insight into the genetic background of many human diseases.
The Genomics Core Facility aims to cover all the needs of modern biomedicine and will offer complex human genome analyses, which could be utilised both in the research projects of other research groups of CEITEC, and also directly in diagnostics and personalised therapy of patients, who would benefit from the knowledge of their genomes (e.g. patients with inherited diseases or oncological and immunological diagnoses). Medical genomics and its potent methodical approaches will become a common aspect of all research groups of the Molecular Medicine Research Programme.
KEY RESEARCH EQUIPMENT
PLANNED RESEARCH INFRASTRUCTURE
Core Facility
The research group will be one of the principal users of the equipment available within CEITEC Genomics Core Facility.
CURRENT RESEARCH INFRASTRUCTURE
Complete workflow for analysis of various types of cancers mainly derived from hematopoietic system – flow cytometry including cell sorting, nucleic acid isolation, PCR, qPCR, sequencing, microarrays, nucleofection, cell culture equipment.
MAIN PROJECTS
- Sensitisation of B-CLL cells to cytostatics by monoclonal antibody rituximab – identification of responsible proteins (NR9301), Ministry of Health, 2007-2009, Martin Trbušek, University Hospital Brno, Jan Havliš, Masaryk University.
SELECTED PUBLICATIONS
- JANIKOVA, A., TICHY, B., SUPIKOVA, J., ET AL. Gene expression profiling in follicular lymphoma and its implication for clinical practice. LEUKEMIA & LYMPHOMA. 2011, 52(1), p. 59-68.
- KOTASKOVA, J., TICHY, B., TRBUSEK, M., ET AL. High Expression of Lymphocyte-Activation Gene 3 (LAG3) in Chronic Lymphocytic Leukemia Cells Is Associated with Unmutated lmmunoglobulin Variable Heavy Chain Region (IGHV) Gene and Reduced Treatment-Free Survival. JOURNAL OF MOLECULAR DIAGNOSTICS. 2010, 12(3), p. 328-334.
- MALCIKOVA, J., TICHY, B., DAMBORSKY, J., KABATHOVA, J., TRBUSEK, M., MAYER, J., POSPISILOVA, S. Analysis of the DNA-binding activity of p53 mutants using functional protein microarrays and its relationship to transcriptional activation. Biological Chemistry. 2010, 391(2-3), p. 197-205.
- EISELLEOVA, L., MATULKA, K., KRIZ, V., ET AL. A Complex Role for FGF-2 in Self-Renewal, Survival, and Adhesion of Human Embryonic Stem Cells. STEM CELLS. 2009, 27(8), p. 1847-1857.
- MRAZ, M., MALINOVA, K., KOTASKOVA, J., PAVLOVA, S., TICHY, B., MALCIKOVA, J., STANO-KOZUBIK, K., SMARDOVA, J., BRYCHTOVA, Y., DOUBEK, M., TRBUSEK, M., MAYER, J., POSPISILOVA, S. miR-34a, miR-29c and miR-17-5p are down-regulated in CLL patients with TP53 abnormalities. Leukemia. 2009, 23(6), p. 1159-1163.
EUROPEAN UNION
